The effect of Tripterygium glycosides tablets combined with rituximab on Wnt/β-catenin signaling pathway and nailfold microcirculation in adult patients with nephrotic syndrome
10.3760/cma.j.cn115455-20241205-01081
- VernacularTitle:雷公藤多苷片联合利妥昔单抗对成年肾病综合征患者Wnt/β-catenin信号通路及甲襞微循环的影响
- Author:
Xiaohan QU
1
;
Ming LI
1
;
Nan ZHANG
1
;
Xinjian LI
1
Author Information
1. 济宁医学院附属医院肾内科，济宁 272007
- Publication Type:Journal Article
- Keywords:
Nephroticsyndrome;
Adult;
Tripterygium;
Rituximab;
Wnt/β-catenin signaling pathway
- From:
Chinese Journal of Postgraduates of Medicine
2025;48(10):928-932
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of Tripterygium glycosides tablets combined with rituximab on the Wnt/β-catenin signaling pathway and nailfold microcirculation in adult patients with nephrotic syndrome (NS).Methods:Eighty adult patients with NS treated in the Affiliated Hospital of Jining Medical College from January 2022 to January 2023 were selected and they were randomly divided into two groups by treatment method, with 40 patients in each group. Both groups were treated with prednisone acetate, while the control group was treated with rituximab. The study group was treated with Tripterygium glycosides tablets based on the control group, and the treatment lasted for 6 months. After treatment for 6 months, the therapeutic effects, Wnt/β-catenin signaling pathway-related mRNA and proteins, nail fold microcirculation index and adverse effects were compared between the two groups.Results:After treatment for 6 months, the total effective rate in the study group was higher than that in the control group : 87.50%(35/40) vs. 67.50%(27/40), there was statistical difference ( χ2 = 4.59, P<0.05). After treatment for 3, 6 months, the levels of Wnt4, β-catenin mRNA and protein were lower than those before treatment, and in the study group were lower than those in the control group :after treatment for 3 months: 4.86 ± 0.55 vs. 6.11 ± 0.70, 5.02 ± 0.68 vs. 5.96 ± 0.74, 3.68 ± 0.61 vs. 4.13 ± 0.66, 3.42 ± 0.55 vs. 4.27 ± 0.59; after treatment for 6 months: 3.12 ± 0.44 vs. 4.59 ± 0.53, 3.05 ± 0.41 vs. 4.11 ± 0.46, 2.00 ± 0.53 vs. 2.86 ± 0.61, 1.24 ± 0.30 vs. 2.67 ± 0.32, there were statistical differences ( P<0.05). After treatment for 3, 6 months, the scores for the flow state and morphology of nailfold microcirculation in the study group were lower than those in the control group: after treatment for 3 months: (1.44 ± 0.26) scores vs. (1.58 ± 0.31) scores, (1.18 ± 0.24) scores vs. (1.49 ± 0.30) scores; after treatment for 6 months: (0.80 ± 0.10) scores vs. (1.38 ± 0.12) scores, (0.97 ± 0.11) scores vs. (1.25 ± 0.12) scores, there were statistical differences ( P<0.05). The incidence of adverse reactions between the two groups had no statistical difference ( P>0.05). Conclusions:The combination of Tripterygium glycosides tablets and rituximab has a definite effect on the treatment of adult NS, which is beneficial for improving nailfold microcirculation. The possible mechanism may be related to the downregulation of the Wnt/β-catenin signaling pathway.
